Soleno Therapeutics Announces Presentations at the 2022 European Congress of Endocrinology
May 19 2022 - 4:05PM
Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a
clinical-stage biopharmaceutical company developing novel
therapeutics for the treatment of rare diseases, today announced
presentations at the upcoming 2022 European Congress of
Endocrinology (ECE), which is being held May 21-24, 2022, in Milan,
Italy.
Details of the presentations are as follows:
2022 European Congress of Endocrinology
(ECE)
|
Title: |
DCCR Update |
| Format: |
Presentation at the International
Prader-Willi syndrome Meeting 2022 organized by INfoRMEd – PWS (the
International Netwrok for Research, Managament and Education on
adults with PWS) and the European Society of Endocrinology |
| Presenter: |
Dr. Evelien Gevers on behalf of
the DESTINY PWS Investigators |
| Date |
Saturday, May 21, 2022 |
| Time: |
12:10 – 12:30 PM CET |
|
Title: |
Long-Term Safety of Diazoxide Choline Extended-Release (DCCR)
Tablets in Patients with Prader-Willi Syndrome |
| Format: |
E-Poster -- Programme Code: EP360
/ Submission Number 2044 |
| Presenter: |
Dr. Evelien Gevers on behalf of
the DESTINY PWS Investigators |
|
Title: |
Comparison of hyperphagia and problem behaviors in participants
with Prader-Willi syndrome (PWS) receiving Diazoxide Choline
Extended-Release (DCCR) with matched participants in PATH for PWS
(PfPWS) |
| Format: |
Poster -- Programme Code: P77 /
Submission Number 789 |
| Presenter: |
Dr. Evelien Gevers on behalf of
the DESTINY PWS Investigators and the PATH for PWS
Investigators |
| Date: |
Sunday, May 22, 2022 |
The copy of the posters will be available in the Investors
section on the Company’s website at www.soleno.life after
presentation at the meeting.
About Soleno Therapeutics, Inc.Soleno is
focused on the development and commercialization of novel
therapeutics for the treatment of rare diseases. The company’s lead
candidate, DCCR, a once-daily oral tablet for the treatment of
Prader-Willi syndrome (PWS), is currently being evaluated in an
ongoing Phase 3 clinical development program. For more information,
please visit www.soleno.life.
Corporate Contact:Brian RitchieLifeSci
Advisors, LLC212-915-2578
Soleno Therapeutics (NASDAQ:SLNO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Soleno Therapeutics (NASDAQ:SLNO)
Historical Stock Chart
From Apr 2023 to Apr 2024
